Emergent BioSolutions Gets $704 Million Ebola Treatment Contract From the U.S.
July 31 2023 - 4:04PM
Dow Jones News
By Dean Seal
A wing of the U.S. Department of Health and Human Services has
awarded Emergent BioSolutions a 10-year contract worth up to $704
million for the development and production of an Ebola virus
treatment.
The Gaithersburg, Md.-based biotechnology company Monday that
the contract comes from the Biomedical Advanced Research and
Development Authority, which is part of the department's
Administration for Strategic Preparedness and Response.
The contract calls for the advanced development, manufacturing
scale-up and procurement of Ebanga, a licensed treatment for Ebola
virus disease.
Shares rose 7.7% to $7.41 in after-market trading.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
July 31, 2023 16:49 ET (20:49 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Apr 2024 to May 2024
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From May 2023 to May 2024
